Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

4,471JPY
5:46am GMT
Change (% chg)

¥221 (+5.20%)
Prev Close
¥4,250
Open
¥4,297
Day's High
¥4,488
Day's Low
¥4,297
Volume
1,770,800
Avg. Vol
1,878,538
52-wk High
¥5,032
52-wk Low
¥3,277

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo Co Ltd Says Ken Keller Appointed President & CEO Of Daiichi Sankyo, Inc., A U.S. Affiliate
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CO LTD - KEN KELLER APPOINTED PRESIDENT & CEO OF DAIICHI SANKYO, INC., A U.S. AFFILIATE.DAIICHI SANKYO CO LTD - JUNICHI KOGA TO BECOME NEW GLOBAL HEAD OF RESEARCH & DEVELOPMENT UNIT.  Full Article

Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For Minnebro Tablets In Japan
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Exelixis Inc ::EXELIXIS’ COLLABORATOR DAIICHI SANKYO RECEIVES REGULATORY APPROVAL FOR MINNEBRO™ (ESAXERENONE) TABLETS FOR THE TREATMENT OF HYPERTENSION IN JAPAN.EXELIXIS INC - APPROVAL ALLOWS FOR MARKETING OF MINNEBRO FOR THE INDICATION WITHIN JAPAN..  Full Article

Daiichi Sankyo Co Ltd, Anheart Therapeutics Entered Into Worldwide Exclusive License Agreement For DS-6051
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CO LTD - CO AND ANHEART THERAPEUTICS ENTERED INTO WORLDWIDE EXCLUSIVE LICENSE AGREEMENT FOR DS-6051.DAIICHI SANKYO CO LTD - FINANCIAL TERMS OF AGREEMENT ARE NOT DISCLOSED.  Full Article

Daiichi Sankyo: Announces Reorganization Scheme For Kitasato Daiichi Sankyo Vaccine
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Japan's Daiichi Sankyo Co Ltd <4568.T>::ANNOUNCES REORGANIZATION SCHEME FOR KITASATO DAIICHI SANKYO VACCINE.  Full Article

Daiichi Sankyo Co, Roche To Collaborate On New HER2 Low Companion Diagnostic Test
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO AND ROCHE TO COLLABORATE ON NEW HER2 LOW COMPANION DIAGNOSTIC TEST.DAIICHI SANKYO- UNDER AGREEMENT, ROCHE WILL SEEK TO DEVELOP, MANUFACTURE & COMMERCIALIZE WORLDWIDE AN IMMUNOHISTOCHEMISTRY COMPANION DIAGNOSTIC TEST.DAIICHI SANKYO CO - SPECIFIC FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED.  Full Article

FDA Grants Priority Review For Daiichi Sankyo's NDA For Quizartinib
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::FDA GRANTS PRIORITY REVIEW FOR DAIICHI SANKYO'S NEW DRUG APPLICATION FOR FLT3 INHIBITOR QUIZARTINIB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY FLT3-ITD AML.DAIICHI SANKYO CO LTD - U.S. FDA HAS ACCEPTED A NDA AND GRANTED PRIORITY REVIEW FOR QUIZARTINIB.DAIICHI SANKYO CO - QUIZARTINIB MARKETING APPLICATIONS NOW UNDER EXPEDITED REVIEW IN U.S., JAPAN AND EU.DAIICHI SANKYO CO - FDA IS EXPECTED TO MAKE A DECISION ON APPROVAL OF QUIZARTINIB BY MAY 25, 2019.  Full Article

Daiichi Sankyo Announces Clinical Research Collaboration With Merck KGaA, Darmstadt, Germany And Pfizer
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO ANNOUNCES CLINICAL RESEARCH COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY AND PFIZER TO EVALUATE FAM- TRASTUZUMAB DERUXTECAN (DS-8201) WITH AVELUMAB AND A DNA DAMAGE RESPONSE INHIBITOR IN PATIENTS WITH HER2 EXPRESSING AND MUTATED SOLID TUMORS.DAIICHI SANKYO CO LTD - ENTERED INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY AND PFIZER, INC.DAIICHI SANKYO - AGREEMENT TO EVALUATE COMBINATION OF FAM- TRASTUZUMAB DERUXTECAN WITH CHECKPOINT INHIBITOR AVELUMAB AND/OR DDR INHIBITOR.  Full Article

FDA Grants Breakthrough Therapy Designation To Daiichi Sankyo's FLT3 Inhibitor Quizartinib
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Daiichi Sankyo Company Limited <4568.T>::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO DAIICHI SANKYO'S FLT3 INHIBITOR QUIZARTINIB FOR RELAPSED/REFRACTORY FLT3-ITD AML.  Full Article

IM issues 2nd tranche convertible bonds worth 7.5 bln won
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - IM Co Ltd <101390.KQ> ::Says it completed issuance of 2nd tranche unregistered and unsecured private convertible bonds worth 7.5 billion won .  Full Article

R&I affirms Daiichi Sankyo's rating at "AA" and says negative outlook-R&I
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I.Rating outlook negative-R&I.  Full Article

Deals of the day-Mergers and acquisitions

March 1 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday: